Copyright
©The Author(s) 2024.
World J Gastroenterol. Feb 28, 2024; 30(8): 863-880
Published online Feb 28, 2024. doi: 10.3748/wjg.v30.i8.863
Published online Feb 28, 2024. doi: 10.3748/wjg.v30.i8.863
Figure 3 Survival curves for (A) progression-free survival and (B) overall survival in the presence or absence of myosteatosis.
PFS: Progression-free survival; OS: Overall survival.
- Citation: Deng GM, Song HB, Du ZZ, Xue YW, Song HJ, Li YZ. Evaluating the influence of sarcopenia and myosteatosis on clinical outcomes in gastric cancer patients undergoing immune checkpoint inhibitor. World J Gastroenterol 2024; 30(8): 863-880
- URL: https://www.wjgnet.com/1007-9327/full/v30/i8/863.htm
- DOI: https://dx.doi.org/10.3748/wjg.v30.i8.863